MBMelanie E. Bennett

Melanie E. Bennett

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Melanie E. Bennett has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Alan S. Bellack

    4 shared publications
  • Jack J. Blanchard

    Department of Psychology, University of Maryland, College Park, MD 20742, USA

    4 shared publications
  • Alan S. Bellack

    University of Maryland School of Medicine , Baltimore , Maryland , USA ; VA Capital Network Mental Illness Research, Education, and Clinical Center , Baltimore , Maryland , USA

    2 shared publications
  • Clayton H. Brown

    VA VISN 5 Mental Illness Research, Education, and Clinical Center , Baltimore , Maryland , USA

    2 shared publications
  • Joanna E. Strong Kinnaman

    Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland, USA; VA Capital Healthcare Network Mental Illness Research, Education, and Clinical Center (MIRECC), Baltimore, Maryland, USA

    2 shared publications
  • Julie M. McCarthy

    Department of Psychology, University of Maryland College Park, College Park, MD 20742, United States; McLean Hospital/Harvard Medical School, Belmont, MA 02478, United States

    2 shared publications

Latest Publications

  • Negative symptoms and the formation of social affiliative bonds in schizophrenia

    by Julie M. McCarthy, Kristen R. Bradshaw, Lauren T. Catalano, Cristina P. Garcia, Asia Malik, Melanie E. Bennett, Jack J. Blanchard


  • Treatment of substance use disorders in schizophrenia

    by Melanie E. Bennett, Kristen R. Bradshaw, Lauren T. Catalano

    Background: Substance use disorders (SUDs) represent a great barrier to functional recovery for individuals with schizophrenia. It is important to use research on treatment of SUDs in schizophrenia to guide treatment recommendations and program planning. Objectives: We review studies of pharmacological and psychosocial interventions to treat SUDs in individuals with schizophrenia. Methods: The criteria used to select studies for inclusion are (1) the percentage of the sample with a schizophrenia spectrum diagnosis is at least 25%; (2) participants have a comorbid SUD or problem use of substances; (3) an intervention for SUD is provided; (4) a substance use-related outcome is measured; and (5) the study design enabled examination of pre–post outcome measures including open label trials, nonrandomized evaluations (quasi-experimental designs, nonrandom assignment to groups), or randomized controlled trials. Results: There are few psychopharmacology outcomes studies. Most have examined use of antipsychotic medications to treat SUDs in schizophrenia. Several trials have yielded positive findings for naltrexone in reducing drinking compared to placebo in this population. Motivational and cognitive-behavioral interventions are associated with decreased substance use in several trials. Conclusion: Treatment for SUDs is feasible within a range of settings and acceptable to many individuals with schizophrenia. All individuals with schizophrenia should be offered brief or more extended psychosocial interventions that incorporate discussion of personal reasons to change and training in cognitive-behavioral strategies to reduce use, cope with cravings and stress, and avoid relapse. Future research must include larger samples, longitudinal designs, and similar outcome measures across studies.


  • Inefficient effort allocation and negative symptoms in individuals with schizophrenia

    by Julie M. McCarthy, Michael T. Treadway, Melanie E. Bennett, Jack J. Blanchard


  • The interactive effects of negative symptoms and social role functioning on suicide ideation in individuals with schizophrenia

    by Danielle R. Jahn, Melanie E. Bennett, Stephanie G. Park, Raquel E. Gur, William P. Horan, Ann M. Kring, Jack J. Blanchard


  • Editorial

    by Melanie Bennett

  • Smoking Cessation in Individuals With Serious Mental Illness: A Randomized Controlled Trial of Two Psychosocial Interventions

    by Melanie E. Bennett, Clayton H. Brown, Lan Li, Seth Himelhoch, Alan Bellack, Lisa Dixon

    Smoking among individuals with serious mental illness is a critical public health problem. Although guidelines recommend bupropion for these smokers, many do not want to use medications for smoking cessation, express ambivalence about identifying a "quit date," and do not have access to behavioral smoking cessation services integrated with mental health care. Individuals with serious mental illness who smoked 10 or more cigarettes per day (N = 178) were randomized to either a multifaceted behavioral group intervention or a supportive group intervention, both of which were integrated within outpatient mental health services at three VA medical centers. Participants attended twice-weekly meetings for 12 weeks, provided information on their smoking at each meeting, and completed baseline and post-treatment assessments conducted by an assessor who was blind to condition. Primary outcomes collected at post-treatment included 1-week abstinence, number of cigarettes smoked per day during the last week, and number of quit attempts during the treatment period. Outcomes examined for a subset of participants who attended at least one intervention meeting (n = 152) included smoking abstinence for 1-, 2-, and 4-week blocks during the treatment period. Analyses conducted on those participants who attended three or more intervention meetings (n = 127) included time to 50% reduction in the number of cigarettes smoked and time to first quit attempt. Sixteen participants achieved abstinence (11.8%), smoking quantity was significantly reduced (baseline M = 15.2, SD = 9.8 to post-treatment M = 7.5, SD = 7.7, p <.0001), and most reported making a quit attempt (n = 88, 72.7%). There were no differences by study condition on any abstinence or reduction outcomes. Significant reductions in number of cigarettes smoked generally took place within the first two weeks; however, these reductions did not often translate into abstinence. Many participants reduced their smoking and sampled quitting during the study. Implementing smoking cessation services in mental health treatment settings is feasible and, if delivered in line with best practices, either a behavioral or a supportive approach can be helpful. Future research should examine ways to facilitate the transition from reduction to abstinence. This study was part of a clinical trial registered as NCT #00960375 at www.clinicaltrials.gov.


  • Smoking Cessation in People with Schizophrenia

    by Melanie E. Bennett, Amy L. Wilson, Margo Genderson, Alice M. Saperstein

    Objective: High rates of smoking and nicotine dependence have a profoundly negative impact on the health and well being of individuals with schizophrenia. Treating smoking is a critical step in improving the health and quality of life of people affected by this illness. This paper reviews the literature on smoking cessation interventions in schizophrenia and discusses potential barriers to effective treatment with this population. Methods: The criteria used to select studies for inclusion were: (1) Sample included 50% or more individuals with schizophrenia spectrum diagnosis (SSD); (2) Some individual or group intervention for smoking cessation was provided; and (3) Some smoking-related outcome variable was measured (self-reported smoking, breath carbon monoxide, etc). Results: Both pharmacologic and psychosocial smoking cessation treatments have been found to be useful in helping individuals with schizophrenia reduce and quit smoking in the short term. Few interventions have been found to be effective in promoting smoking abstinence in the long term. Conclusions: Intervention development must include strategies to overcome barriers to smoking cessation that are most relevant to individuals with schizophrenia and focus on translating short term gains into long term abstinence.


  • A Review of Android Apps for Smoking Cessation

    by Melanie E. Bennett, Kristin Toffey, Faith Dickerson, Seth Himelhoch, Emily Katsafanas, Christina L.G. Savage

    Introduction: The use of applications (apps) on smartphones and tablet devices is a fast growing component of health behaviour change efforts, including smoking cessation. While the content and utility of iPhone apps for smoking cessation have been systematically reviewed, Android apps have not been examined.Aims: This study reviewed and evaluated free Android apps for smoking cessation available for download from Google Play and Amazon's USA homepage in January 2013.Methods: Apps were reviewed; those targeting smoking cessation were identified and examined to ensure that they targeted tobacco smoking and were focused on quitting. Remaining apps were independently rated by three reviewers for 24 clinical strategies for smoking cessation. Results: Overall, 284 free apps were identified using the search terms ‘quit smoking’, ‘smoking cessation’, and ‘stop smoking’; 113 apps that targeted smoking cessation were downloaded for further review. Of these, 21 targeted tobacco smoking and were focused on quitting. These apps had moderate to low ratings for the 24 strategies, indicating that they lacked several of the most helpful strategies for quitting smoking. The apps were strongest in helping users track the number of cigarettes smoked. None connected users to on-line sources of support, referred users to smoking cessation counselling, or recommended the use of nicotine replacement therapies.Conclusions: While Android apps for smoking cessation have some strengths, they would benefit from incorporating a broader range of strategies for helping people quit smoking.


  • The Motivation and Pleasure Scale–Self-Report (MAP-SR): Reliability and validity of a self-report measure of negative symptoms

    by Katiah Llerena, Stephanie G. Park, Julie M. McCarthy, Shannon M. Couture, Melanie E. Bennett, Jack J. Blanchard


  • Impact of Family History in Persons With Dual Diagnosis

    by Camille S. Wilson, Melanie E. Bennett, Alan S. Bellack

    Objective: This study examined relationships among family history of alcohol, drug, and psychiatric problems and substance use severity, interpersonal relationships, and service use in individuals with dual diagnosis. Methods: Data were collected with the family history section of the Addiction Severity Index administered as part of three studies of individuals with dual disorders (N = 413). Participants were categorized into family history risk groups for each problem domain based on the number of first- and second-degree relatives with alcohol, drug, or psychiatric problems. Results: Rates of alcohol, drug, and psychiatric problems were high across family member categories and highest overall for siblings. More than two-thirds of the sample was categorized in the high-risk group in the alcohol problem domain, almost half of the sample was categorized as high-risk in the drug problem domain, and more than a third of the sample was categorized as high-risk in the psychiatric problem domain. Across problem domains, individuals in the high-risk group reported more relationship problems with parents and siblings and higher rates of lifetime emotional, physical, and sexual abuse than did those in the low- or moderate-risk groups. Conclusions: Family history of alcohol, drug, and psychiatric problems is associated with greater rates of poor family relationships and history of abuse. Assessment of these different forms of family history in multiple family members can aid treatment providers in identifying individuals with dual disorders who may benefit from trauma-informed care as part of their overall mental health and substance abuse treatment services.